Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
46.58
+0.18 (0.38%)
Nov 21, 2024, 3:34 PM EST - Market open
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for RARE stock have an average target of 86.79, with a low estimate of 46 and a high estimate of 127. The average target predicts an increase of 86.34% from the current stock price of 46.58.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RARE stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 6 |
| Buy | 8 | 8 | 9 | 9 | 9 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 15 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $121 | Strong Buy | Maintains | $121 | +159.80% | Nov 12, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $109 → $121 | Strong Buy | Maintains | $109 → $121 | +159.80% | Nov 6, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $77 | Buy | Reiterates | $77 | +65.32% | Nov 6, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $116 | Buy | Reiterates | $116 | +149.06% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $82 → $95 | Strong Buy | Maintains | $82 → $95 | +103.97% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
552.76M
from 434.25M
Increased by 27.29%
Revenue Next Year
653.92M
from 552.76M
Increased by 18.30%
EPS This Year
-6.33
from -8.25
EPS Next Year
-5.21
from -6.33
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 581.4M | 826.4M | 1.2B | ||
| Avg | 552.8M | 653.9M | 915.1M | ||
| Low | 522.8M | 575.3M | 682.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 33.9% | 49.5% | 90.2% | ||
| Avg | 27.3% | 18.3% | 39.9% | ||
| Low | 20.4% | 4.1% | 4.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.74 | -3.83 | -0.66 | ||
| Avg | -6.33 | -5.21 | -3.15 | ||
| Low | -6.56 | -6.03 | -5.32 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.